The purpose of this legislation, known as the "Skinny Labels, Big Savings Act," is to create protections for companies that develop generic drugs and biological products. It aims to ensure that these companies can seek approval for their products without infringing on certain patents related to how those drugs are used. This is intended to encourage competition in the pharmaceutical market, ultimately leading to lower prices for consumers.